Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2003-02-07 Major Shareholding Noti…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2003
Major Shareholding Notification
2003-02-07 English
FORM 8-K DATED JANUARY 7, 2003
Delisting Announcement Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 7, 2003. It announces the transfer of the company's stock listing from the Nasdaq National Market to the Nasdaq SmallCap Market. The document is short (2030 characters) and primarily serves as an announcement of this event, including a press release as an exhibit. There are no financial statements or detailed financial data included. The content fits the definition of a Delisting Announcement (DLST) because it officially notifies the market of a change in the stock exchange listing status. Therefore, the correct classification is DLST with high confidence.
2003-01-08 English
FORM 8-K DATED DECEMBER 17, 2002
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 17, 2002. It is a current report pursuant to the Securities Exchange Act of 1934. The content includes an announcement of a strategic adjustment to the company's business strategy and references a press release attached as Exhibit 99.1. There are no financial statements or detailed financial data included in the text. The document is short (2062 characters) and primarily serves as a regulatory announcement of an event rather than a detailed financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2002-12-18 English
SCHEDULE 13D/A #4
Major Shareholding Notification
2002-12-06 English
FORM 8-K DATED DECEMBER 4, 2002
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a notification about the termination of a collaborative agreement, and it references a press release as an exhibit. The document is short (2052 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2002-12-04 English
FORM 10-Q FOR PERIOD ENDED 09/30/2002
Interim / Quarterly Report Q3 2002
2002-11-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.